AstraZeneca (AZN) Tops Q3 EPS by 4c; Reaffirms FY12 Outlook

AstraZeneca (NYSE: AZN) reported Q3 EPS of $1.51, $0.04 better than the analyst estimate of $1.47. Revenue for the quarter came in at $6.68 billion versus the consensus estimate of $6.61 billion.

Reported EPS in the quarter was $1.22.

AstraZeneca reaffirmed FY2012 guidance.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• CoStar Group acquires Zonda for $800M, adding new home data
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions